BofA Securities Reiterates Neutral Rating on Agilent (A) following Biocare Medical acquisition announcement
Tweet Send to a Friend
BofA Securities analyst Michael Ryskin reiterated a Neutral rating and $150.00 price target on Agilent (NYSE: A)The analyst commented, "Earlier ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
